A Review of Theranostics: Perspectives on Emerging Approaches and                     Clinical Advancements

Burkett, Brian J.; Bartlett, David J.; McGarrah, Patrick Walsh; Lewis, Akeem R.; Johnson, Derek R.; Berberoğlu, Kezban; Pandey, Mukesh K.; Packard, Ann T.; Halfdanarson, Thorvardur R.; Hruska, Carrie B.; Johnson, G.A.; Kendi, Ayse T.

doi:10.1148/rycan.220157

Cited by 24 publications

(9 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combined therapy and diagnostic functions, or theranostic potentials, have been generally limited to radiotracer/therapy molecules and nanoparticles [ 50 , 51 ], including 177 Lu-trastuzumab (Herceptin), 177 Lu-DOTATATE, and 177 Lu-FAPI-46, specifically for breast cancer [ 52 ]. Ultrasounds have been used such as the high-intensity focused ultrasound (HIFU) for breast cancer ablation, yet the current HIFU is limited primarily to thermally sensitive MR-guidance and some attempts at standard US guidance in China [ 53 ].…”

Section: The Future Of Dynamic Focusing For Therapymentioning

confidence: 99%

Breast Tomographic Ultrasound: The Spectrum from Current Dense Breast Cancer Screenings to Future Theranostic Treatments

Littrup,

Mehrmohammadi,

Duric

2024

Tomography

View full text Add to dashboard Cite

This review provides unique insights to the scientific scope and clinical visions of the inventors and pioneers of the SoftVue breast tomographic ultrasound (BTUS). Their >20-year collaboration produced extensive basic research and technology developments, culminating in SoftVue, which recently received the Food and Drug Administration’s approval as an adjunct to breast cancer screening in women with dense breasts. SoftVue’s multi-center trial confirmed the diagnostic goals of the tissue characterization and localization of quantitative acoustic tissue differences in 2D and 3D coronal image sequences. SoftVue mass characterizations are also reviewed within the standard cancer risk categories of the Breast Imaging Reporting and Data System. As a quantitative diagnostic modality, SoftVue can also function as a cost-effective platform for artificial intelligence-assisted breast cancer identification. Finally, SoftVue’s quantitative acoustic maps facilitate noninvasive temperature monitoring and a unique form of time-reversed, focused US in a single theranostic device that actually focuses acoustic energy better within the highly scattering breast tissues, allowing for localized hyperthermia, drug delivery, and/or ablation. Women also prefer the comfort of SoftVue over mammograms and will continue to seek out less-invasive breast care, from diagnosis to treatment.

show abstract

Section: The Future Of Dynamic Focusing For Therapymentioning

confidence: 99%

Breast Tomographic Ultrasound: The Spectrum from Current Dense Breast Cancer Screenings to Future Theranostic Treatments

Littrup,

Mehrmohammadi,

Duric

2024

Tomography

View full text Add to dashboard Cite

show abstract

“…Still those approaches have their own detection-limits and their artifacts, lowering their diagnostic accuracy. − An emerging field trying to cover this gap and provide the clinicians with more options into their repertoire is nuclear medicine. A field dedicated to the development of radiopharmaceuticals aiming for diagnosis with the use of single photon emission tomography (SPECT) or positron emission tomography (PET), and/or therapy with the deployment of radiotoxic payloads to tumor sites. − …”

Section: Introductionmentioning

confidence: 99%

Two Novel [⁶⁸Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar¹¹]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer

Kanellopoulos,

Bezverkhniaia,

Abouzayed

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Gastrin releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PC-3) and can be used for diagnostic purposes. We herein present the design and preclinical evaluation of two novel NOTA/NODAGA-containing peptides suitable for labeling with the positron emission tomography (PET) radionuclide Ga-68. These analogs are based on the previously reported GRPR-antagonist DOTAGA-PEG2-[Sar 11 ]RM26, developed for targeted radiotheraostic applications. Both NOTA-PEG2-[Sar 11 ]RM26 and NODAGA-PEG2-[Sar 11 ]RM26 were successfully labeled with Ga-68 and evaluated in vitro and in vivo using PC-3 cell models. Both, [ 68 Ga]Ga-NOTA-PEG2-[Sar 11 ]RM26 and [ 68 Ga]Ga-NODAGA-PEG2-[Sar 11 ]RM26 displayed high metalchelate stability in phosphate buffered saline and against the EDTA-challenge. The two [ 68 Ga]Ga-labeled conjugates demonstrated highly GRPR-mediated uptake in vitro and in vivo and exhibited a slow internalization over time, typical for radioantagonistis. The [ nat Ga]Ga-loaded peptides displayed affinity in the low nanomole range for GRPR in competition binding experiments. The new radiotracers demonstrated biodistribution profiles suitable for diagnostic imaging shortly after administration with fast background clearance. Their high tumor uptake (13 ± 1 and 15 ± 3% IA/g for NOTA and NODAGA conjugates, respectively) and high tumor-to-blood ratios (60 ± 10 and 220 ± 70, respectively) 3 h pi renders them promising PET tracers for use in patients. Tumor-to-normal organ ratios were higher for [ 68 Ga]Ga-NODAGA-PEG2- [Sar 11 ]RM26 than for the NOTA-containing counterpart. The performance of the two radiopeptides was further supported with the PET/CT images. In conclusion, [ 68 Ga]Ga-NODAGA-PEG2-[Sar 11 ]RM26 is a promising PET imaging tracer for visualization of GRPR-expressing lesions with high imaging contrast shortly after administration.

show abstract

“…Along this trajectory, there have been endeavors to produce PARP ligands labeled with radionuclides suitable for imaging via single photon computed emission tomography/computed tomography (SPECT/CT) or positron emission computed tomography (PET/CT) [24,25]. This aims to enhance patient selection for enrollment in PARP-targeted therapies, according to the so-called "theranostic" approach [26]. Theranostics is an innovative platform based on the administration of two molecules targeting the same tumorassociated biomarker, the first labeled with a radionuclide suitable for imaging and the second one conjugated with a radionuclide emitting particle exerting anti-tumor effects.…”

Section: Introductionmentioning

confidence: 99%

PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview

Filippi,

Urso,

Evangelista

2024

CIMB

View full text Add to dashboard Cite

Auger electrons (AEs) represent an intriguing topic in the field of radionuclide therapy. They are emitted by several radionuclides commonly used in nuclear medicine (indium-111, iodine-123, iodine-125), allowing for highly localized energy deposition and thus exerting a radiotoxic effect on specific cellular and sub-cellular targets. However, due to their short range in matter, AEs have had limited use in therapeutic applications so far. In recent years, the synthesis of various radiopharmaceuticals capable of binding to the enzyme poly(ADP-ribose) polymerase 1 has reignited interest in this type of therapy, laying the groundwork for a theranostic approach based on radionuclides emitting AEs. The enzyme PARP-1 operates enzymatically in close proximity to DNA that represents the prime target of radionuclide therapies. Following this trend, several PARP-targeted radiopharmaceuticals for AE-based theranostics have been developed. We provide an updated overview of preclinical studies focused on the applications of this new theranostic approach in glioblastoma, breast, prostate and ovarian carcinoma, and pancreatic adenocarcinoma.

show abstract

A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements

Cited by 24 publications

References 87 publications

Breast Tomographic Ultrasound: The Spectrum from Current Dense Breast Cancer Screenings to Future Theranostic Treatments

Breast Tomographic Ultrasound: The Spectrum from Current Dense Breast Cancer Screenings to Future Theranostic Treatments

Two Novel [⁶⁸Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar¹¹]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer

PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview

Contact Info

Product

Resources

About

A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements

Cited by 24 publications

References 87 publications

Breast Tomographic Ultrasound: The Spectrum from Current Dense Breast Cancer Screenings to Future Theranostic Treatments

Breast Tomographic Ultrasound: The Spectrum from Current Dense Breast Cancer Screenings to Future Theranostic Treatments

Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer

PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview

Contact Info

Product

Resources

About

Two Novel [⁶⁸Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar¹¹]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer